Advances in science and the sequencing of the human genome have led to the 1st FDA approved gene therapy for Leber’s Congenital Amaurosis, specifically targeted to the eye. The eye is unique given its immune-privileged status, giving ophthalmology an advantage for success. Treatments hold promise for our patients but are not without ethical dilemmas which we have dealt with and continue to navigate along the way. This talk will review the history of gene therapy, the specifics of FDA approval and what may be ahead.
- Clinical eye care
- Medical Students
- Community Physicians
Participants who engage in this educational intervention will be able to:
- Provide an overview of the principles and history of gene therapy
- Describe why the eye is a target for gene therapy
- Discuss FDA approved gene therapies
- Discuss ongoing gene therapy trials and future possibilities
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
Deborah M. Costakos, MD
Ophthalmology and Visual Sciences
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.00 hours of participation for continuing education for allied health professionals.
The Medical College of Wisconsin, Inc. is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 150930. This program has been approved for up to 1.00 contact hours of continuing education (which includes 1.00 hours of pharmacology). Nurse Practitioners should claim only those hours actually spent participating in the CME activity.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.